导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.67% | 1924/4773 |
| 近一周 | -1.77% | 3282/5467 |
| 近一月 | 4.93% | 46/5421 |
| 近一季 | 6.58% | 293/5238 |
| 近半年 | 4.02% | 974/4931 |
| 近一年 | 4.07% | 1755/4400 |
| 近两年 | 38.86% | 1936/2954 |
| 近三年 | 47.54% | 600/2253 |
| 成立以来 | 69.69% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.77% 2899/4961 |
-8.20% 3857/5312 |
- - |
- - |
| 2025 | 10.70% 2793/4813 |
2.56% 1337/3635 |
11.59% 156/4076 |
-8.48% 4039/4524 |
5.68% 412/4813 |
| 2024 | 39.17% 28/3463 |
10.04% 81/2808 |
6.82% 127/3014 |
12.39% 2360/3129 |
5.35% 614/3463 |
| 2023 | -2.71% 601/2656 |
-2.47% 1993/2280 |
1.80% 199/2385 |
4.68% 137/2515 |
-6.39% 1745/2655 |
| 2022 | -4.28% 87/2207 |
2.29% 60/1919 |
-1.37% 1715/2016 |
-8.13% 172/2113 |
3.27% 733/2208 |
| 2021 | -1.17% 786/1822 |
10.13% 47/1255 |
-2.59% 1219/1330 |
-7.20% 1032/1466 |
-0.73% 1271/1822 |
| 2020 | -0.44% 943/1250 |
-13.84% 942/1028 |
2.00% 981/1067 |
4.36% 957/1164 |
8.55% 669/1184 |
| 2019 | 27.23% 553/1092 |
14.82% 696/739 |
2.36% 86/788 |
1.62% 381/850 |
6.53% 598/918 |
| 2018 | -12.34% 82/834 |
- - |
-10.49% 318/631 |
10.95% 12/660 |
-9.66% 157/682 |
| 2017 | 17.79% 219/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.86% 137/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证银行ETF联接C VS. 长安沪深300非周期A(740101) |